[{"id":"3c19bae1-0bb5-4981-9c9a-f622527c42f9","acronym":"MCLA-158-CL01","url":"https://clinicaltrials.gov/study/NCT03526835","created_at":"2023-02-28T17:01:26.541Z","updated_at":"2025-02-25T17:36:01.506Z","phase":"Phase 1/2","brief_title":"A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT03526835 - MCLA-158-CL01","lead_sponsor":"Merus N.V.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR amplification","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • petosemtamab (MCLA-158)"],"overall_status":"Recruiting","enrollment":" Enrollment 523","initiation":"Initiation: 05/02/2018","start_date":" 05/02/2018","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2027","study_completion_date":" 11/01/2027","last_update_posted":"2025-01-29"},{"id":"42eaa2bb-da4a-4921-abda-242b6741daf6","acronym":"KL140-Ⅲ-02-CTP","url":"https://clinicaltrials.gov/study/NCT04835142","created_at":"2021-04-08T13:52:28.774Z","updated_at":"2025-02-25T16:16:06.277Z","phase":"Phase 3","brief_title":"Comparison of A140 and Erbitux Combined With mfolfox6 to Evaluate Efficacy and Safety of First-line Treatment for Ras Wild-type mCRC","source_id_and_acronym":"NCT04835142 - KL140-Ⅲ-02-CTP","lead_sponsor":"Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.","biomarkers":" KRAS • BRAF • NRAS","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF wild-type • BRAF V600 wild-type","tags":["KRAS • BRAF • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF wild-type • BRAF V600 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • Datalai (cetuximab biosimilar)"],"overall_status":"Completed","enrollment":" Enrollment 688","initiation":"Initiation: 12/31/2020","start_date":" 12/31/2020","primary_txt":" Primary completion: 03/22/2023","primary_completion_date":" 03/22/2023","study_txt":" Completion: 01/26/2024","study_completion_date":" 01/26/2024","last_update_posted":"2024-08-05"},{"id":"049acb0a-e716-4715-af42-f30f1499423c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05750290","created_at":"2023-03-01T15:02:17.647Z","updated_at":"2024-07-02T16:35:54.451Z","phase":"Phase 2","brief_title":"CKD-702 Plus Irinotecan in Gastric Cancer","source_id_and_acronym":"NCT05750290","lead_sponsor":"National Cancer Center, Korea","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR overexpression • MET overexpression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR overexpression • MET overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan • CKD-702"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 12/01/2022","start_date":" 12/01/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-03-01"},{"id":"68b53629-bd68-4ac5-8c30-b43bdf31b541","acronym":"","url":"https://clinicaltrials.gov/study/NCT05552807","created_at":"2022-09-23T17:07:08.783Z","updated_at":"2024-07-02T16:36:03.566Z","phase":"Phase 1","brief_title":"SCT200 in Combination With SCT-I10A/Paclitaxel/Docetaxel in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma","source_id_and_acronym":"NCT05552807","lead_sponsor":"Sinocelltech Ltd.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • docetaxel • SCT200 • Anyouping (finotonlimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 06/15/2022","start_date":" 06/15/2022","primary_txt":" Primary completion: 09/01/2023","primary_completion_date":" 09/01/2023","study_txt":" Completion: 09/01/2023","study_completion_date":" 09/01/2023","last_update_posted":"2022-09-23"},{"id":"12703e6d-ae4a-48dc-8f0f-c5ca0a1dc374","acronym":"","url":"https://clinicaltrials.gov/study/NCT04466254","created_at":"2021-01-18T21:27:57.019Z","updated_at":"2024-07-02T16:36:26.025Z","phase":"Phase 2","brief_title":"Efficacy and Safety Study of Combination of CPGJ602 and Chemotherapy, in First Line, With Wild KRAS/NRAS/BRAF in Metastatic Colorectal Cancer","source_id_and_acronym":"NCT04466254","lead_sponsor":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","biomarkers":" KRAS • BRAF","pipe":" | ","alterations":" KRAS wild-type • BRAF wild-type • NRAS wild-type • BRAF wild-type + NRAS wild-type","tags":["KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • BRAF wild-type • NRAS wild-type • BRAF wild-type + NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • oxaliplatin • CPGJ-602"],"overall_status":"Recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 12/07/2020","start_date":" 12/07/2020","primary_txt":" Primary completion: 12/30/2021","primary_completion_date":" 12/30/2021","study_txt":" Completion: 03/30/2022","study_completion_date":" 03/30/2022","last_update_posted":"2021-08-23"},{"id":"da41551a-8725-4ada-8cf7-99ed7c4f6360","acronym":"","url":"https://clinicaltrials.gov/study/NCT04739111","created_at":"2022-06-29T09:02:24.631Z","updated_at":"2024-07-02T16:36:34.938Z","phase":"Phase 1","brief_title":"An Exploratory Clinical Study of LDP Combined With CDP1 in Patients With Advanced Malignant Tumor","source_id_and_acronym":"NCT04739111","lead_sponsor":"Dragonboat Biopharmaceutical Company Limited","biomarkers":" RAS","pipe":"","alterations":" ","tags":["RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BC001 (cetuximab biosimilar) • lesabelimab (BC003)"],"overall_status":"Recruiting","enrollment":" Enrollment 130","initiation":"Initiation: 01/29/2021","start_date":" 01/29/2021","primary_txt":" Primary completion: 02/01/2023","primary_completion_date":" 02/01/2023","study_txt":" Completion: 02/01/2024","study_completion_date":" 02/01/2024","last_update_posted":"2021-02-08"},{"id":"9aab6e3e-4ea5-4f7e-8b27-9b27341ac1de","acronym":"","url":"https://clinicaltrials.gov/study/NCT04151810","created_at":"2021-01-18T20:15:59.672Z","updated_at":"2024-07-02T16:36:53.959Z","phase":"Phase 1","brief_title":"Phase I Clinical Trial of CDP1 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT04151810","lead_sponsor":"Dragonboat Biopharmaceutical Company Limited","biomarkers":" BRAF • RAS • CUX1","pipe":"","alterations":" ","tags":["BRAF • RAS • CUX1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BC001 (cetuximab biosimilar)"],"overall_status":"Unknown status","enrollment":" Enrollment 30","initiation":"Initiation: 12/30/2019","start_date":" 12/30/2019","primary_txt":" Primary completion: 12/30/2020","primary_completion_date":" 12/30/2020","study_txt":" Completion: 06/30/2021","study_completion_date":" 06/30/2021","last_update_posted":"2019-11-05"},{"id":"71f19e4c-e061-4785-8b02-3310ad3641cc","acronym":"","url":"https://clinicaltrials.gov/study/NCT03491709","created_at":"2021-01-18T17:11:47.995Z","updated_at":"2024-07-02T16:36:54.076Z","phase":"Phase 1","brief_title":"A Preliminary Clinical Study on the Pharmacokinetics and Safety of CDP1 in Patients With Advanced CRC or HNSCC","source_id_and_acronym":"NCT03491709","lead_sponsor":"Dragonboat Biopharmaceutical Company Limited","biomarkers":" CUX1","pipe":"","alterations":" ","tags":["CUX1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • BC001 (cetuximab biosimilar)"],"overall_status":"Unknown status","enrollment":" Enrollment 18","initiation":"Initiation: 07/01/2018","start_date":" 07/01/2018","primary_txt":" Primary completion: 09/17/2019","primary_completion_date":" 09/17/2019","study_txt":" Completion: 12/01/2019","study_completion_date":" 12/01/2019","last_update_posted":"2019-10-31"},{"id":"b49f819c-3089-400b-a64f-32198fb43ffd","acronym":"SCT200-D101","url":"https://clinicaltrials.gov/study/NCT03808701","created_at":"2022-06-14T03:01:22.781Z","updated_at":"2024-07-02T16:37:03.731Z","phase":"Phase 1","brief_title":"Efficacy and Safety of SCT200 in Patients With Advanced Squamous Non-small Cell Lung Cancer","source_id_and_acronym":"NCT03808701 - SCT200-D101","lead_sponsor":"Sinocelltech Ltd.","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SCT200"],"overall_status":"Unknown status","enrollment":" Enrollment 50","initiation":"Initiation: 03/01/2019","start_date":" 03/01/2019","primary_txt":" Primary completion: 12/01/2019","primary_completion_date":" 12/01/2019","study_txt":" Completion: 12/01/2019","study_completion_date":" 12/01/2019","last_update_posted":"2019-01-17"},{"id":"7a27f60b-044a-4f80-ab02-778fc2ffe60c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03692689","created_at":"2021-01-18T18:05:54.721Z","updated_at":"2024-07-02T16:37:06.476Z","phase":"Phase 2","brief_title":"Safety and Efficacy of SCT200 in Patients With Relapsed or Metastatic Triple Receptor Negative Breast Cancer","source_id_and_acronym":"NCT03692689","lead_sponsor":"Sinocelltech Ltd.","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative • PGR expression","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SCT200"],"overall_status":"Unknown status","enrollment":" Enrollment 30","initiation":"Initiation: 07/20/2018","start_date":" 07/20/2018","primary_txt":" Primary completion: 09/30/2019","primary_completion_date":" 09/30/2019","study_txt":" Completion: 12/31/2019","study_completion_date":" 12/31/2019","last_update_posted":"2018-10-02"},{"id":"c6a655e7-53e0-46e6-851e-d6f3a57c6d35","acronym":"","url":"https://clinicaltrials.gov/study/NCT03356158","created_at":"2021-01-18T16:34:02.068Z","updated_at":"2024-07-02T16:37:06.867Z","phase":"Phase 1","brief_title":"A Study of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Metastatic Colorectal Cancer","source_id_and_acronym":"NCT03356158","lead_sponsor":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","biomarkers":" KRAS • CEACAM5 • CA 19-9","pipe":"","alterations":" ","tags":["KRAS • CEACAM5 • CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • CPGJ-602"],"overall_status":"Unknown status","enrollment":" Enrollment 21","initiation":"Initiation: 11/15/2017","start_date":" 11/15/2017","primary_txt":" Primary completion: 10/30/2018","primary_completion_date":" 10/30/2018","study_txt":" Completion: 11/30/2018","study_completion_date":" 11/30/2018","last_update_posted":"2018-09-17"},{"id":"0bf022e3-2504-4bd9-ab06-f6c2ad181d2c","acronym":"KL140-III-01","url":"https://clinicaltrials.gov/study/NCT03426371","created_at":"2021-01-18T16:54:11.832Z","updated_at":"2025-02-25T16:15:44.799Z","phase":"Phase 3","brief_title":"Epidermal Growth Factor Receptor (EGFR) Antagonist Chimeric Anti-EGFR Monoclonal Antibody Trial","source_id_and_acronym":"NCT03426371 - KL140-III-01","lead_sponsor":"Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.","biomarkers":" BRAF • RAS","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF wild-type • RAS wild-type • BRAF V600 wild-type","tags":["BRAF • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF wild-type • RAS wild-type • BRAF V600 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e oxaliplatin • leucovorin calcium • Datalai (cetuximab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 570","initiation":"Initiation: 02/01/2018","start_date":" 02/01/2018","primary_txt":" Primary completion: 12/01/2020","primary_completion_date":" 12/01/2020","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2018-02-08"},{"id":"cbdbff1d-60cf-4b40-bc6a-1d9ccfb23dae","acronym":"","url":"https://clinicaltrials.gov/study/NCT03405272","created_at":"2021-01-18T16:48:07.688Z","updated_at":"2024-07-02T16:37:14.636Z","phase":"Phase 2","brief_title":"Safety and Efficacy of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Wild-type RAS and BRAF mCRC","source_id_and_acronym":"NCT03405272","lead_sponsor":"Sinocelltech Ltd.","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF wild-type","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SCT200"],"overall_status":"Unknown status","enrollment":" Enrollment 110","initiation":"Initiation: 02/12/2018","start_date":" 02/12/2018","primary_txt":" Primary completion: 12/01/2018","primary_completion_date":" 12/01/2018","study_txt":" Completion: 12/01/2019","study_completion_date":" 12/01/2019","last_update_posted":"2018-01-23"}]